Sign Up to like & get
recommendations!
0
Published in 2020 at "Acta Pharmacologica Sinica"
DOI: 10.1038/s41401-020-0399-1
Abstract: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, remains a major challenge in the targeted therapy of non-small cell lung cancer (NSCLC). HKB99 is a novel allosteric inhibitor of…
read more here.
Keywords:
allosteric inhibitor;
inhibitor;
erlotinib resistant;
invasive pseudopodia ... See more keywords